Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
NEW YORK (Reuters Health) – The incidence of esophageal adenocarcinoma in patients with nondysplastic Barrett’s esophagus is lower than previously reported, so less rigorous surveillance may be possible,…
NEW YORK (Reuters Health) – For patients with acute malignant obstruction of the left-sided colon, placement of colonic stents as a bridge to elective surgery offers no advantage…
David B. Solit, MD, Elizabeth and Felix Rohatyn Chair for Junior Faculty, Memorial Sloan-Kettering Cancer Center, discusses B-Raf, an intracellular signaling protein.B-Raf is commonly mutated in cancer, and…
NEW YORK (Reuters Health) – A negative sentinel lymph node (SLN) biopsy in patients with melanoma is associated with a low likelihood of disease recurrence involving the lymph…
NEW YORK (Reuters Health) – Combined with ondansetron and dexamethasone, a single intravenous dose of fosaprepitant is as effective as a standard 3-day oral course of aprepitant for…
NEW YORK (Reuters Health) – Adrenal involvement is rare in cases of renal cell carcinoma, even when the tumor is large or in the upper pole. Therefore, concurrent…
NEW YORK (Reuters Health) – Methylene blue has certain advantages over isosulfan blue in sentinel lymph node procedures, but the risk of a palpable mass at the injection…
NEW YORK (Reuters Health) – Women undergoing emetogenic surgical procedures are less likely to have postoperative nausea and vomiting when treated with ondansetron plus casopitant than with ondansetron…
NEW YORK (Reuters Health) – For women with thyroid cancer treated with radioiodine-131, subsequent pregnancy is safe without adverse outcomes for the offspring. That’s according to a report…
NEW YORK (Reuters Health) – The anti-EGFR antibody cetuximab added to two state-of-the-art regimens for metastatic colorectal cancer produces favorable response rates with manageable toxicity, a German team…
